Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Propanc Biopharma Inc PPCB

Healthcare Biotechnology
Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from... see more

Recent & Breaking News (OTCPK:PPCB)

Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells

Business Wire March 16, 2023

Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer

Business Wire November 30, 2022

Propanc Biopharma's CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer

Business Wire November 15, 2022

Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027

Business Wire September 29, 2022

Propanc Biopharma Provides Shareholder Update

Business Wire September 13, 2022

Propanc Biopharma Reports Significant Effects of PRP Against the Tumor Microenvironment

Business Wire September 8, 2022

Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office

Business Wire August 16, 2022

Propanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research & Drug Discovery Program

Business Wire July 19, 2022

Propanc Biopharma's CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients

Business Wire July 12, 2022

Propanc Biopharma's CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global Jurisdictions

Business Wire July 5, 2022

Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split

Business Wire June 24, 2022

Propanc Biopharma's CSO Hails Dostarlimab's Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer

Business Wire June 22, 2022

Propanc Biopharma's PRP to Target 80 - 90% of Cancer Cases

Business Wire June 14, 2022

Propanc Biopharma Believes PRP Reduced Toxicity Will Impact Cancer Patient Lives Significantly

Business Wire June 1, 2022

Propanc Biopharma Presents 100 Years of Clinical Evidence for "Novel" Enzyme Therapeutic Approach to Treat Cancer

Business Wire May 26, 2022

Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use

Business Wire May 18, 2022

Propanc Biopharma Offers a Novel Way to Stop Cancer

Business Wire May 11, 2022

Propanc Biopharma Purchases Pharma Grade Raw Materials for PRP Manufacture in Preparation for Phase I First-In-Human Study

Business Wire May 2, 2022

Propanc Biopharma's Management Explains Why They Believe Cancer Patients Are Likely to Respond to PRP Treatment

Business Wire April 13, 2022

Propanc Biopharma's CEO Expresses Concern Over Disruption to Cancer Care During Global Pandemic

Business Wire April 6, 2022